Dr. Roof Introduces Overlay Roofing Installation Option for Qualified Homes in Southern California
Dr. Roof now offers overlay roofing to help Southern California homeowners save time, reduce project costs, and limit construction waste.
'Overlay installations are not a universal solution, but in the right scenario, they offer a technically sound alternative.'— Dr. Roof
CALABASAS, CA, UNITED STATES, June 15, 2025 / EINPresswire.com / -- Dr. Roof, a licensed and insured roofing contractor operating throughout Southern California, has announced the availability of overlay roofing installations for qualified residential properties. The method, also known as 're-roofing,' offers an alternative to full roof replacement for homes where the existing roofing structure remains intact and suitable for a secondary layer.
This update to Dr. Roof's service offerings reflects an effort to align with evolving building practices, where roofing options are increasingly tailored to structural conditions, regional building codes, and waste reduction efforts.
'Overlay installations are not a universal solution, but in the right scenario, they offer a technically sound alternative,' said a spokesperson for Dr. Roof. 'They're considered after a full inspection confirms the roof's suitability.'
Overlay roofing involves placing a new layer of roofing material —typically asphalt shingles—over an existing layer. According to industry practice, this can only be done when the existing material is stable, dry, and not part of a roof with more than one previous layer, which is often the maximum allowed under many local codes.
Dr. Roof evaluates homes individually to determine eligibility, taking into account structural soundness, drainage design, material type, and overall condition. Homes with moisture damage, sagging, or code violations are not candidates for overlay installation and are instead directed toward full roof replacement options.
The company notes that the overlay process may reduce labor time and debris, though this is dependent on roof slope, configuration, and local permit requirements. Each project follows standard permit acquisition procedures and manufacturer compliance checks.
This expansion of roofing options comes at a time when homeowners and contractors alike are exploring practical, regulation-aligned alternatives for maintaining residential structures, especially in regions like Southern California where climate, cost, and construction waste are important considerations.
In addition to overlay installation, Dr. Roof provides:
1. Asphalt shingle and tile roof replacements
2. Flat roof evaluations and installations
3. Roof repairs and inspections
4. Cool Roof system options that meet California Title 24 compliance
Dr. Roof emphasizes that overlay installations are offered only when code and safety standards are met, and the company continues to educate clients on the pros and limitations of the method during on-site evaluations.
Dr. Roof
Trusted Full-Service Roofing Contractor
+1 310-928-2773
[email protected]
Visit us on social media:
Facebook
Other
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
15 minutes ago
- Wall Street Journal
How the Federal Reserve Fuels Fiscal Profligacy
If Republicans are serious about reducing federal deficit spending, it is important to consider the effect the Federal Reserve has on the nation's budgetary outlook. If the numerical models imposed by the Congressional Budget Office drive fiscal policy, lawmakers also need to understand what they portend for monetary policy. The Fed once was committed to 'normalizing' its balance sheet—shrinking its footprint in credit markets by reducing the size of its portfolio of Treasury debt and mortgage-backed securities. Chairman Jerome Powell noted in a 2019 speech that large-scale asset purchases by the Fed over the previous 10 years had been viewed from the outset as 'extraordinary measures to be unwound, or 'normalized,' when conditions ultimately warranted.'
Yahoo
23 minutes ago
- Yahoo
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Rare earth supply risks: Is Tesla the real target by China?
-- With China granting rare earth export licenses to GM, Ford, and Stellantis (NYSE:STLA) but not to Tesla (NASDAQ:TSLA), questions are mounting over whether Tesla is being deliberately targeted amid ongoing trade tensions and Musk's outspoken foreign policy stance. 'Media reports only indicate GM, F & STLA received licenses. This implies TSLA & RIVN could still be waiting for licenses. It's possible this is the consequence of Musk's aggressive stance on foreign policy & China's aim to support local EV makers,' Wells Fargo wrote, citing expert Dr. Gracelin Baskaran. China controls nearly 100% of global supply for the seven most critical heavy rare earth elements, or REEs, which are essential for electric vehicle motors and other advanced manufacturing. The U.S. auto sector is the largest end-user of these materials, but America's consumption is a fraction of global output—just 6,600 tonnes out of 390,000 tonnes produced last year. Following China's April 4 restrictions, automakers had only 2-3 months of buffer stock, and those reserves are now running low. While the six-month licenses keep operations running for some U.S. automakers, Wells Fargo warns the current arrangement is 'still a band-aid, not a fix,' with supply risks likely to persist for another two to five years as new capacity ramps up outside China. For now, China's selectivity in granting licenses and vigilance over end-use means Tesla—and other OEMs still waiting—could face mounting pressure until global rare earth supply chains diversify. Related articles Rare earth supply risks: Is Tesla the real target by China? 2025 Global Technology Conference: What did we learn? Has AI started replacing junior software developers? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
